Ajanta Pharma spurted 12.73% to Rs 825 at 14:18 IST on BSE after net profit surged 155% to Rs 56 crore on 50% growth in revenue from operations to Rs 280 crore in Q2 September 2013 over Q2 September 2012.
The Q2 result was announced during trading hours today, 28 October 2013.
Meanwhile, the S&P BSE Sensex was down 94.66 points or 0.46% at 20,588.86.
The stock surged on high volumes. On BSE, 3.47 lakh shares were traded in the counter as against average daily volume of 22,630 shares in the past one quarter.
The stock hit a high of Rs 858.95 so far during the day, which is also its record high for the counter. The stock hit a low of Rs 730.25 so far during the day. The stock had hit a 52-week low of Rs 235.53 on 12 November 2012.
The stock had underperformed the market over the past one month till 25 October 2013, declining 0.83% compared with the Sensex's 4.17% rise. The scrip had also underperformed the market in past one quarter, advancing 4.38% as against Sensex's 4.44% rise.
More From This Section
The small-cap company has equity capital of Rs 17.58 crore. Face value per share is Rs 5.
Ajanta Pharma's EBITDA (earnings before interest, taxation, depreciation and amortization) jumped 95% to Rs 84 crore in Q2 September 2013 over Q2 September 2012. EBITDA margin increased to 30% from 23% a year ago.
Exports contributed 64% of the total operating income in Q2 September 2013.
Commenting on the company's Q2 performance, Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma said, "we are pleased with healthy results for the quarter driven by India and emerging markets. We remain focused on select speciality therapeutic segments in India and select geographies in overseas market. We continue to stretch boundaries of excellence and building quality business on the already laid strong foundation with focus on growing sales and profitability consistently".
Ajanta Pharma filed 3 more abbreviated new drug applications (ANDAs) during the quarter taking total tally to 18 ANDAs (2 approved and 16 awaiting approval).
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets.
Powered by Capital Market - Live News